ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2025-8-3-18-26ojrdrt-462Research ArticleЛУЧЕВАЯ ТЕРАПИЯRADIOTHERAPYЭффективность бор-нейтронзахватной терапии в лечении пациентов злокачественными опухолями головы и шеи, систематический обзорEfficacy of Boron Neutron Capture Therapy for Head and Neck Cancer: Systematic Reviewhttps://orcid.org/0000-0002-3275-2886ВыжигинаБ. Б.VyzhiginaB. B.

Выжигина Белла Борисовна 

117152, Москва, Загородное шоссе, 18А 

Bella B. Vyzhigina 

117152 Moscow, Zagorodnoye Shosse, 18A 

vyz.bella@gmail.comhttps://orcid.org/0000-0001-7185-7165ДолгушинБ. И.DolgushinB. I.

115478, Москва, Каширское шоссе, 24 

24 Kashirskoye Shosse, Moscow, 115478 

https://orcid.org/0000-0002-9132-3416КропотовМ. А.KropotovM. A.

249031, Обнинск, ул. Маршала Жукова, 10

249031, Obninsk, 10 Zhukova str. 

Онкологический центр №1 ГКБ им. С.С. Юдина Департамента здравоохраненияРоссияOncology Center No. 1 of S.S. Yudin City Clinical Hospital of the Department of HealthRussian FederationНациональный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian FederationМедицинский радиологический научный центр имени А.Ф. Цыба — филиал НМИЦ радиологииРоссияA.F. Tsyb Medical Radiological Research Centre — branch of the National Medical Research Radiological CentreRussian Federation202523092025831826Copyright © Выжигина Б.Б., Долгушин Б.И., Кропотов М.А., 20252025Выжигина Б.Б., Долгушин Б.И., Кропотов М.А.Vyzhigina B.B., Dolgushin B.I., Kropotov M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/462Введение

Введение: Рак головы и шеи характеризуется высокой частотой локорегионарных рецидивов. Лечение прогрессирующего заболевания малоэффективно, что существенно ухудшает прогноз пациентов. В связи с этим актуально изучение бор-нейтронзахватной терапии (БНЗТ) как перспективного метода, способного обеспечить селективное уничтожение опухолевых клеток при минимальном повреждении окружающих тканей.

Цель систематического обзора — комплексная оценка эффективности и безопасности БНЗТ при местно-распространенном, рецидивном раке органов головы и шеи.

Материалы и методы

Материалы и методы: Следуя рекомендациям PRISMA (предпочтительные элементы отчетности для систематических обзоров и мета-анализов), мы провели систематический поиск в PubMed всех статей по январь 2025 г.

Результаты

Результаты: 22 исследования было включено в систематический обзор: 8 исследований I/II фазы и одно исследование II фазы, а также 11 ретроспективых работ. Поиск выявил 680 пациентов с рецидивными либо местно-распространенными нерезектабельными злокачественными новообразованиями органов головы и шеи. Анализ показал, что БНЗТ демонстрирует многообещающую эффективность при различных видах рака с управляемым профилем безопасности.

Выводы

Выводы: БНЗТ демонстрирует существенные перспективы в качестве метода лечения, предлагая потенциальные преимущества с приемлемыми профилями безопасности. Тем не менее, необходимы дальнейшие исследования для совершенствования его клинического применения и обеспечения безопасности и эффективности.

Introduction. Head and neck cancer is characterized by a high rate of locoregional relapses. Treatment of progressive disease is ineffective, which significantly reduces the prognosis. The importance to study boron neutron capture therapy (BNCT) as a promising method capable of providing selective destruction of tumor cells with minimal damage to surrounding tissues.The aim of this systematic review was to comprehensively evaluate the efficacy and safety of BNCT in locally advanced recurrent head and neck cancer.Materials and methods: Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we conducted a systematic search of PubMed for all articles up to January 2025.Results: 22 studies were included in the systematic review: 8 phase I/II studies and one phase II study, as well as 11 retrospective studies. The search identified 680 patients with recurrent or locally advanced unresectable head and neck cancer. The analysis showed that BNCT demonstrates promising efficacy in various cancer types with a manageable safety profile. Conclusions: BNCT shows significant promise as a treatment modality, offering potential benefits with acceptable safety. However, further research is needed to improve its clinical application and ensure its safety and efficacy.

БНЗТбор-нейтронзахватной терапиялучевая терапиярак органов головы и шеиBNCTboron neutron capture therapyradiation therapyhead and neck cancerReferencesBray F, Laversanne M, Sung H. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwidefor 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229- 63. https://doi.org/10.3322/caac.21834Bray F, Laversanne M, Sung H. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwidefor 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229- 63. https://doi.org/10.3322/caac.21834Dong L, Xue L, Cheng W, et al. Comprehensive survival analysis of oral squamous cell carcinoma patients undergoing initial radical surgery. BMC Oral Health. 2024;24(1):919. https://doi.org/10.1186/s12903-024-04690-zDong L, Xue L, Cheng W, et al. Comprehensive survival analysis of oral squamous cell carcinoma patients undergoing initial radical surgery. BMC Oral Health. 2024;24(1):919. https://doi.org/10.1186/s12903-024-04690-zGuntinas-Lichius O, Kreppel MP, Stuetzer H, et al. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol. 2007;33(2):222-28. https://doi.org/10.1016/j.ejso.2006.10.033Guntinas-Lichius O, Kreppel MP, Stuetzer H, et al. Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol. 2007;33(2):222-28. https://doi.org/10.1016/j.ejso.2006.10.033Yang KL, Chi MS, Hao CY, et al. Phase II clinical trial assessing the addition of hyperthermia to salvage concurrent chemoradiotherapy for unresectable recurrent head and neck cancer. Radiat Oncol. 2025;20(1):21. https://doi.org/10.1186/s13014-025-02585-zYang KL, Chi MS, Hao CY, et al. Phase II clinical trial assessing the addition of hyperthermia to salvage concurrent chemoradiotherapy for unresectable recurrent head and neck cancer. Radiat Oncol. 2025;20(1):21. https://doi.org/10.1186/s13014-025-02585-zLee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):731-40. https://doi.org/10.1016/j.ijrobp.2006.12.055Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):731-40. https://doi.org/10.1016/j.ijrobp.2006.12.055Baselga J, Trigo JM, Bourhis J, et al. Phase II study of cetuximab plus platinum-based chemotherapy in platinum-refractory metastatic head and neck cancer. J Clin Oncol. 2005;23(24):5568-77. https://doi.org/10.1200/JCO.2005.07.119Baselga J, Trigo JM, Bourhis J, et al. Phase II study of cetuximab plus platinum-based chemotherapy in platinum-refractory metastatic head and neck cancer. J Clin Oncol. 2005;23(24):5568-77. https://doi.org/10.1200/JCO.2005.07.119Ferris RL, Blumenschein GJ, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-67. https://doi.org/10.1056/NEJMoa1602252Ferris RL, Blumenschein GJ, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856-67. https://doi.org/10.1056/NEJMoa1602252Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-27. https://doi.org/10.1056/NEJMoa0802656Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-27. https://doi.org/10.1056/NEJMoa0802656Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head and neck cancer. Int J Radiat Oncol Biol Phys. 2006;64(2):382-91. https://doi.org/10.1016/j.ijrobp.2005.07.005Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head and neck cancer. Int J Radiat Oncol Biol Phys. 2006;64(2):382-91. https://doi.org/10.1016/j.ijrobp.2005.07.005Sewnaik A, Keereweer S, Al-Mamgani A, et al. High complication risk of salvage surgery after chemoradiation failures. Acta Otolaryngol. 2012;132:96-100. https://doi.org/10.3109/00016489.2011.617779Sewnaik A, Keereweer S, Al-Mamgani A, et al. High complication risk of salvage surgery after chemoradiation failures. Acta Otolaryngol. 2012;132:96-100. https://doi.org/10.3109/00016489.2011.617779Dionisi F, Fiorica F, D’Angelo E, et al. Organs at risk’s tolerance and dose limits for head and neck cancer re-irradiation: a literature review. Oral Oncol. 2019;98:35-47. https://doi.org/10.1016/j.oraloncology.2019.08.017Dionisi F, Fiorica F, D’Angelo E, et al. Organs at risk’s tolerance and dose limits for head and neck cancer re-irradiation: a literature review. Oral Oncol. 2019;98:35-47. https://doi.org/10.1016/j.oraloncology.2019.08.017Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy vs cetuximab with chemotherapy in recurrent/metastatic head and neck cancer (KEYNOTE-048). Lancet. 2019;394:1915-28. https://doi.org/10.1016/S0140-6736(19)32591-7Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy vs cetuximab with chemotherapy in recurrent/metastatic head and neck cancer (KEYNOTE-048). Lancet. 2019;394:1915-28. https://doi.org/10.1016/S0140-6736(19)32591-7Patachi B, Jensen KH, Gothelf A, et al. Pembrolizumab as firstline treatment for recurrent/metastatic head and neck cancer: single-centre data. Acta Oncol. 2025;64:143-46. https://doi.org/10.2340/1651-226X.2025.42128Patachi B, Jensen KH, Gothelf A, et al. Pembrolizumab as firstline treatment for recurrent/metastatic head and neck cancer: single-centre data. Acta Oncol. 2025;64:143-46. https://doi.org/10.2340/1651-226X.2025.42128Zhou T, Igawa K, Kasai T, et al. The current status and novel advances of boron neutron capture therapy clinical trials. Am J Cancer Res. 2024;14(2):429-47. https://doi.org/10.62347/HBBE6868Zhou T, Igawa K, Kasai T, et al. The current status and novel advances of boron neutron capture therapy clinical trials. Am J Cancer Res. 2024;14(2):429-47. https://doi.org/10.62347/HBBE6868Moher MD, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097Moher MD, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097Wittig A, Collette L, Appelman K, et al. EORTC Trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck. J Cell Mol Med. 2009;13:1653-65. https://doi.org/10.1111/j.1582-4934.2009.00856.xWittig A, Collette L, Appelman K, et al. EORTC Trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck. J Cell Mol Med. 2009;13:1653-65. https://doi.org/10.1111/j.1582-4934.2009.00856.xHirose K, Konno A, Hiratsuka J, et al. BNCT using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): an open-label phase II trial. Radiother Oncol. 2021;155:182-87. https://doi.org/10.1016/j.radonc.2020.11.001Hirose K, Konno A, Hiratsuka J, et al. BNCT using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): an open-label phase II trial. Radiother Oncol. 2021;155:182-87. https://doi.org/10.1016/j.radonc.2020.11.001Aihara T, Morita N, Kamitani N, et al. Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck. Int J Clin Oncol. 2014;19:437-44. https://doi.org/10.1007/s10147-013-0580-3Aihara T, Morita N, Kamitani N, et al. Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck. Int J Clin Oncol. 2014;19:437-44. https://doi.org/10.1007/s10147-013-0580-3Aihara T, Morita N. BNCT for advanced or recurrent head and neck cancer. Neutron Capture Therapy: Principles and Applications. Springer; 2012:417-24. https://doi.org/10.1016/j.apradiso.2014.04.007Aihara T, Morita N. BNCT for advanced or recurrent head and neck cancer. Neutron Capture Therapy: Principles and Applications. Springer; 2012:417-24. https://doi.org/10.1016/j.apradiso.2014.04.007Kankaanranta L, Seppälä T, Koivunoro H, et al. BNCT for locally recurred head and neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2012;82:e67-e75. https://doi.org/10.1016/j.ijrobp.2010.09.057Kankaanranta L, Seppälä T, Koivunoro H, et al. BNCT for locally recurred head and neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2012;82:e67-e75. https://doi.org/10.1016/j.ijrobp.2010.09.057Kankaanranta L, Seppälä T, Koivunoro H, et al. BNCT in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:475-82. https://doi.org/10.1016/j.ijrobp.2007.03.039Kankaanranta L, Seppälä T, Koivunoro H, et al. BNCT in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:475-82. https://doi.org/10.1016/j.ijrobp.2007.03.039Wang LW, Chen YW, Ho CY, et al. Fractionated BNCT in locally recurrent head and neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys. 2016;95:396-403. https://doi.org/10.1016/j.ijrobp.2016.02.028Wang LW, Chen YW, Ho CY, et al. Fractionated BNCT in locally recurrent head and neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys. 2016;95:396-403. https://doi.org/10.1016/j.ijrobp.2016.02.028Wang LW, Chen YW, Ho CY, et al. Fractionated BNCT for locally recurrent head and neck cancer: experience from a phase I/II trial at Tsing Hua Open-Pool Reactor. Appl Radiat Isot. 2014;88:23-27. https://doi.org/10.1016/j.apradiso.2013.11.134Wang LW, Chen YW, Ho CY, et al. Fractionated BNCT for locally recurrent head and neck cancer: experience from a phase I/II trial at Tsing Hua Open-Pool Reactor. Appl Radiat Isot. 2014;88:23-27. https://doi.org/10.1016/j.apradiso.2013.11.134Lee JC, Chuang KS, Liu YW, et al. Comparison of dose distributions in gross tumor volume between BNCT alone and BNCT plus IMRT for head and neck cancer. PLoS One. 2019;14:e0210626. https://doi.org/10.1371/journal.pone.0210626Lee JC, Chuang KS, Liu YW, et al. Comparison of dose distributions in gross tumor volume between BNCT alone and BNCT plus IMRT for head and neck cancer. PLoS One. 2019;14:e0210626. https://doi.org/10.1371/journal.pone.0210626Wang LW, Liu YH, Chu PY, et al. BNCT followed by image-guided IMRT for locally recurrent head and neck cancer: a prospective phase I/II trial. Cancers (Basel). 2023;15(10):2762. https://doi.org/10.3390/cancers15102762Wang LW, Liu YH, Chu PY, et al. BNCT followed by image-guided IMRT for locally recurrent head and neck cancer: a prospective phase I/II trial. Cancers (Basel). 2023;15(10):2762. https://doi.org/10.3390/cancers15102762Koivunoro H, Kankaanranta L, Seppälä T, et al. BNCT for locally recurrent head and neck squamous cell carcinoma: an analysis of dose response and survival. Radiother Oncol. 2019;137:153-58. https://doi.org/10.1016/j.radonc.2019.04.033Koivunoro H, Kankaanranta L, Seppälä T, et al. BNCT for locally recurrent head and neck squamous cell carcinoma: an analysis of dose response and survival. Radiother Oncol. 2019;137:153-58. https://doi.org/10.1016/j.radonc.2019.04.033Haapaniemi A, Kankaanranta L, Saat R, et al. BNCT in the treatment of recurrent laryngeal cancer. Int J Radiat Oncol Biol Phys. 2016;95:404-10. https://doi.org/10.1016/j.ijrobp.2015.11.010Haapaniemi A, Kankaanranta L, Saat R, et al. BNCT in the treatment of recurrent laryngeal cancer. Int J Radiat Oncol Biol Phys. 2016;95:404-10. https://doi.org/10.1016/j.ijrobp.2015.11.010Higashino M, Aihara T, Takeno S, et al. BNCT as a larynx-preserving treatment for locally recurrent laryngeal carcinoma after conventional radiation therapy: a preliminary report. Auris Nasus Larynx. 2024;51(4):792-96. https://doi.org/10.1016/j.anl.2024.06.007Higashino M, Aihara T, Takeno S, et al. BNCT as a larynx-preserving treatment for locally recurrent laryngeal carcinoma after conventional radiation therapy: a preliminary report. Auris Nasus Larynx. 2024;51(4):792-96. https://doi.org/10.1016/j.anl.2024.06.007Sato M, Hirose K. Efficacy and safety of BNCT for hypopharyngeal/laryngeal cancer in previously irradiated patients. Radiother Oncol. 2024;198:110382. https://doi.org/10.1016/j.radonc.2024.110382Sato M, Hirose K. Efficacy and safety of BNCT for hypopharyngeal/laryngeal cancer in previously irradiated patients. Radiother Oncol. 2024;198:110382. https://doi.org/10.1016/j.radonc.2024.110382Kikuoka Y, Aihara T, Higashino M, et al. LAT1 expression in high-grade parotid carcinoma and potential of BNCT as a treatment option. Appl Radiat Isot. 2025;218:111657. https://doi.org/10.1016/j.apradiso.2024.111657Kikuoka Y, Aihara T, Higashino M, et al. LAT1 expression in high-grade parotid carcinoma and potential of BNCT as a treatment option. Appl Radiat Isot. 2025;218:111657. https://doi.org/10.1016/j.apradiso.2024.111657Suzuki M, Kato I, Aihara T, et al. BNCT outcomes for advanced or recurrent head and neck cancer. J Radiat Res. 2014;55(1):146-53. https://doi.org/10.1093/jrr/rrt098Suzuki M, Kato I, Aihara T, et al. BNCT outcomes for advanced or recurrent head and neck cancer. J Radiat Res. 2014;55(1):146-53. https://doi.org/10.1093/jrr/rrt098Wang LW, Wang SI, Chu PY, et al. BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial. Appl Radiat Isot. 2011;69:1803-06. https://doi.org/10.1016/j.apradiso.2011.03.008Wang LW, Wang SI, Chu PY, et al. BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial. Appl Radiat Isot. 2011;69:1803-06. https://doi.org/10.1016/j.apradiso.2011.03.008Kimura Y, Ariyoshi Y, Shimahara M, et al. BNCT for recurrent oral cancer and cervical lymph node metastasis. Appl Radiat Isot. 2009;67(Suppl 7-8):S47-49. https://doi.org/10.1016/j.apradiso.2009.03.019Kimura Y, Ariyoshi Y, Shimahara M, et al. BNCT for recurrent oral cancer and cervical lymph node metastasis. Appl Radiat Isot. 2009;67(Suppl 7-8):S47-49. https://doi.org/10.1016/j.apradiso.2009.03.019Lan TL, Chang FC, Wang CW, et al. Prevention and early management of carotid blowout syndrome in patients receiving salvage BNCT. J Dent Sci. 2021;16(3):854-60. https://doi.org/10.1016/j.jds.2020.12.013Lan TL, Chang FC, Wang CW, et al. Prevention and early management of carotid blowout syndrome in patients receiving salvage BNCT. J Dent Sci. 2021;16(3):854-60. https://doi.org/10.1016/j.jds.2020.12.013Sato M, Hirose K, Takeno S, et al. Safety and efficacy of BNCT with Borofalan (10B) for recurrent head and neck cancer: real-world post-marketing outcomes. Cancers (Basel). 2024;16(5):869. https://doi.org/10.3390/cancers16050869Sato M, Hirose K, Takeno S, et al. Safety and efficacy of BNCT with Borofalan (10B) for recurrent head and neck cancer: real-world post-marketing outcomes. Cancers (Basel). 2024;16(5):869. https://doi.org/10.3390/cancers16050869Takeno S, Yoshino Y, Aihara T, et al. Preliminary outcomes of BNCT for head and neck cancers under public insurance in Japan: real-world experiences. Cancer Med. 2024;13(11):e7250. https://doi.org/10.1002/cam4.7250Takeno S, Yoshino Y, Aihara T, et al. Preliminary outcomes of BNCT for head and neck cancers under public insurance in Japan: real-world experiences. Cancer Med. 2024;13(11):e7250. https://doi.org/10.1002/cam4.7250Suzuki M, Sakurai Y, Nagata Y, et al. Impact of intra-arterial boron administration on dose-volume histograms in BNCT for recurrent head and neck tumors. Int J Radiat Oncol Biol Phys. 2006;66:1523-27. https://doi.org/10.1016/j.ijrobp.2006.07.1373Suzuki M, Sakurai Y, Nagata Y, et al. Impact of intra-arterial boron administration on dose-volume histograms in BNCT for recurrent head and neck tumors. Int J Radiat Oncol Biol Phys. 2006;66:1523-27. https://doi.org/10.1016/j.ijrobp.2006.07.1373Ariyoshi Y, Miyatake SI, Kimura Y, et al. BNCT using epithermal neutrons for recurrent cancer in oral cavity and cervical lymph nodes. Oncol Rep. 2007;18(4):861-66. https://doi.org/10.3892/or.18.4.861Ariyoshi Y, Miyatake SI, Kimura Y, et al. BNCT using epithermal neutrons for recurrent cancer in oral cavity and cervical lymph nodes. Oncol Rep. 2007;18(4):861-66. https://doi.org/10.3892/or.18.4.861Agra IM, Carvalho AL, Ulbrich FS, et al. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck. 2006;28:107-13. https://doi.org/10.1002/hed.20309Agra IM, Carvalho AL, Ulbrich FS, et al. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck. 2006;28:107-13. https://doi.org/10.1002/hed.20309Rivera F, García-Castaño A, Vega N, et al. Cetuximab in metastatic/recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther. 2009;9(10):1421-28. https://doi.org/10.1586/era.09.113.Rivera F, García-Castaño A, Vega N, et al. Cetuximab in metastatic/recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther. 2009;9(10):1421-28. https://doi.org/10.1586/era.09.113.

The authors declare that there are no conflicts of interest present.